UGGT Antibodies

Santa Cruz Biotechnology features a diverse variety of UGGT Antibodies for research focused on UDP-glucose glycoprotein glucosyltransferase (UGGT) and its role in protein folding and quality control within the endoplasmic reticulum. Monoclonal UGGT Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). UGGT plays a central role in the glycoprotein folding process by recognizing and targeting misfolded proteins for degradation, which helps maintain cellular homeostasis. The significance of UGGT extends to various physiological processes, including immune response and cellular stress management. Research into UGGT mechanisms continues to reveal important connections to diseases associated with protein misfolding and aggregation. UDP-glucose glycoprotein glucosyltransferase (UGGT) research has advanced our understanding of cellular quality control systems and their impact on human health. Investigating UGGT pathways has opened new possibilities for therapeutic interventions in protein folding disorders. Santa Cruz Biotechnology monoclonal UGGT Antibodies enable researchers worldwide to advance scientific knowledge and potentially develop new therapeutic strategies for protein misfolding diseases.